First Header Logo Second Header Logo

Connection

David Caudell to Drug Evaluation, Preclinical

Back to Details
This is a "connection" page, showing publications David Caudell has written about Drug Evaluation, Preclinical.
David Caudell
Connection Strength
0.031
Drug Evaluation, Preclinical
  1. Cook GJ, Caudell DL, Elford HL, Pardee TS. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One. 2014; 9(11):e112619.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.